Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell therapy
Biotech
Janux's shares jump 130% following T-cell engager data drop
Janux Therapeutics’ executives aren’t the only ones celebrating positive interim phase 1 data from two tumor-focused candidates.
James Waldron
Feb 27, 2024 10:35am
Boehringer inks second 3T deal, swelling max payday to $538.5M
Jan 4, 2024 7:45am
AbbVie ends Caribou CAR-T deal, continuing cascade of axed pacts
Sep 27, 2023 6:00am
Precision punts early-phase CAR-T to Imugene for $21M upfront
Aug 16, 2023 4:00am
CERo to 60: Engineered T-cell biotech takes blank check route
Jun 5, 2023 11:09am
Cellectis culls CAR-T over cost of kick-starting slow trial
May 5, 2023 8:20am